People · Operator
Named in public records as an officer, director or promoter · active 2008–2021 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Horizon Therapeutics Inc | — | Pharmaceuticals | Series B | $37.0M | $272.0M | 2008 |
| Revelation Biosciences, Inc | — | Biotechnology | Series A | $10.5M | $119.0M | 2020 |
George F. Tidmarsh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside George F. Tidmarsh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Louis C. Bock | 1 | 7 |
| Jeffrey W. Bird | 1 | 6 |
| Jeff Himawan | 1 | 4 |
| Timothy P. Walbert | 1 | 3 |
| Jeffrey W. Sherman | 1 | 2 |
| Curt F. LaBelle | 1 | 1 |
| Chester S. Zygmont | 1 | 1 |
| Barry L. Golombik | 1 | 1 |
| Robert J. De Vaere | 1 | 1 |
| Jeff F. Himawan | 1 | 1 |
| Chester S. Zygmont III | 1 | 1 |
| Jennifer F. Carver | 1 | 1 |
| Jess F. Roper | 1 | 1 |
| James M. Rolke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.